Relating to a study on the use of psychedelic therapies in the treatment of certain conditions.
relating to a study on the use of psychedelic therapies in the
treatment of certain conditions.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. (a) In this Act:
(1) “Department” means the Department of State Health
Services.
(2) “Psychedelic therapies” means the use of
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or ketamine
to treat mental health or other medical conditions.
(b) The department, in consultation with Baylor College of
Medicine and the Center for Psychedelic Research and Therapy at
Dell Medical School at The University of Texas at Austin, shall
conduct a study on the use of psychedelic therapies for treatment of
post-traumatic stress disorder, depression, and other co-occurring
conditions.
(c) In conducting the study, the department shall:
(1) review clinical trials on the efficacy of using
psychedelic therapies in the treatment of post-traumatic stress
disorder, depression, and other co-occurring conditions;
(2) review current literature regarding the use of
psychedelic therapies in the treatment of post-traumatic stress
disorder, depression, and other co-occurring conditions;
(3) review actions of the United States Food and Drug
Administration regarding psychedelic therapies for treatment of
post-traumatic stress disorder, depression, and other co-occurring
conditions;
(4) evaluate treatment guidelines for use of
psychedelic therapies to treat post-traumatic stress disorder,
depression, and other co-occurring conditions and recommend
guidelines and best practices for providers; and
(5) evaluate patient access to current treatment for
post-traumatic stress disorder, depression, and other co-occurring
conditions and recommend legislative or other actions necessary to
ensure patient access to psychedelic therapies following approval
by the United States Food and Drug Administration, including
considerations of provider availability, affordability,
accessibility, training and licensure, and other regulatory
requirements.
(d) Not later than December 1, 2026, the department shall
submit to the governor, the lieutenant governor, the speaker of the
house of representatives, and the chair of the standing committee
of each house of the legislature with primary jurisdiction over the
department a written report that includes:
(1) the results of the study conducted under this
section; and
(2) any recommendations for legislative or other
action necessary to ensure patient access to psychedelic therapies
for treatment of post-traumatic stress disorder, depression, and
other co-occurring conditions after those therapies are approved by
the United States Food and Drug Administration.
(e) This Act expires September 1, 2027.
SECTION 2. This Act takes effect September 1, 2025.
